Medication adherence in older people with rheumatoid arthritis is lower according to electronic monitoring than according to pill count

Suboptimal medication adherence is a serious problem in the treatment of chronic inflammatory diseases. To measure medication adherence, electronic monitoring is regarded as superior to pill count. GLORIA is an ongoing two-year trial on the addition of low-dose (5 mg/d) prednisolone or placebo to st...

Full description

Saved in:
Bibliographic Details
Published in:Rheumatology (Oxford, England) England), 2021-11, Vol.60 (11), p.5239-5246
Main Authors: Hartman, Linda, Cutolo, Maurizio, Bos, Reinhard, Opris-Belinski, Daniela, Kok, Marc R, Griep-Wentink, Hanneke J R M, Klaasen, Ruth, Allaart, Cornelia F, Bruyn, George A W, Raterman, Hennie G, Voshaar, Marieke J H, Gomes, Nuno, Pinto, Rui M A, Klausch, L Thomas, Lems, Willem F, Boers, M
Format: Article
Language:English
Subjects:
Aged
Aged, 80 and over
Arthritis, Rheumatoid - drug therapy
Clinical Science
Drug Packaging - statistics & numerical data
Female
Glucocorticoids - therapeutic use
Humans
Male
Medication Adherence - statistics & numerical data
Prednisolone - therapeutic use
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Suboptimal medication adherence is a serious problem in the treatment of chronic inflammatory diseases. To measure medication adherence, electronic monitoring is regarded as superior to pill count. GLORIA is an ongoing two-year trial on the addition of low-dose (5 mg/d) prednisolone or placebo to standard care in older people (65+ years) with RA. During the entire trial, adherence is measured with electronic caps, and with pill counts. The objective is to describe medication adherence patterns, and to compare the adherence results of the two methods. The recorded adherence patterns of patients (blinded for treatment group) were classified according to descriptive categories. The cutoff for good adherence was set at 80% of prescribed pills taken. Trial inclusion closed in 2018 at 451 patients, but trial follow-up is ongoing; the current dataset contains adherence data of 371 patients. Mean number of recorded 90-day periods per patient was 4 (range 1-8). Based on pill count over all periods, 90% of the patients had good adherence; based on cap data, only 20%. Cap data classified 30% of patients as non-user (
ISSN:1462-0324
1462-0332
DOI:10.1093/rheumatology/keab207